Sanofi is experiencing “a period of intermittent supply” of its Lantus SoloStar insulin pens in the U.S. amid rising demand, the drugmaker confirmed to Becker’s July 24. Lantus SoloStar is a prefilled pen that delivers insulin glargine, a long-acting insulin…

About one-third of U.S. communities lacked a preferred pharmacy in Medicare Part D plans in 2024, with rural areas facing the greatest access gaps, according to a July 22 study published in The American Journal of Managed Care. Researchers analyzed…

Over the past decade, e-prescribing has become nearly universal, reaching 96% of all prescriptions, and real-time benefit tools built to show providers a patient’s cost and coverage at the point of prescribing are now used by more than 90% of…

Arkansas Attorney General Tim Griffin has filed a lawsuit against 13 drug manufacturers and data management firm Second Sight Solutions, alleging they unlawfully restricted healthcare providers’ access to 340B drug discounts in violation of state law. The July 22 lawsuit…

Active U.S. drug shortages increased to 227 in the second quarter of 2026, marking the third consecutive quarterly increase, according to the American Society of Health-System Pharmacists. Nearly half of all new shortages this year involve medications made by a…

A generic version of the allergy medication Zyrtec is being recalled nationwide because of potential cross-contamination with ranitidine, a heartburn drug. Unique Pharmaceutical Laboratories voluntarily recalled four lots of Cetirizine Hydrochloride Tablets USP 5 milligrams after a pharmacy technician identified…

The American Society of Health-System Pharmacists’ House of Delegates approved 16 new policies during its June meeting. The policies will guide ASHP’s advocacy work and are aimed at shaping pharmacy practice going forward, according to a July 21 news release.…

President Donald Trump plans to place tariffs on generic drug imports, building on the 100% tariff he imposed on patented pharmaceutical products in April. While that policy exempted generic drugs and biosimilars for the time being, the White House said…

The U.S. Court of Appeals for the District of Columbia Circuit ruled July 21 that drugmakers cannot implement proposed 340B rebate models without approval from the HHS secretary, affirming lower court rulings in favor of the agency. The case involved…

The FDA has granted full approval for selpercatnib in the treatment of advanced cancer among patients ages 2 and older who carry a rare genetic alteration. Selpercatinib, also known as Retevmo, targets and “turns off” the RET gene fusion to…